Table 3

Changes in disease activity score (DAS) with rituximab versus etanercept or adalimumab/infliximab after propensity score stratification in switching to rituximab compared with switching to alternative tumour necrosis factor antagonists

RituximabEtanerceptAdalimumab/infliximab
DAS28Mean (SD)N†Mean (SD)N†p Value*Mean (SD)N†p Value*
6 months−1.61 (1.56)221−1.32 (1.41)1080.19−1.04 (1.33)1430.001
9 months−1.35 (1.54) 78−1.66 (1.44) 500.79−1.39 (1.48) 720.36
12 months−1.81 (1.60)121−1.66 (1.49) 780.36−1.55 (1.49)1040.05
  • *p Value compared with rituximab.

  • †Number of patients with data available at time intervals defined in the Methods section.